```html

Juvenile Chronic Arthritis (Pauci‑articular)

Overview

Juvenile chronic arthritis (JCA) is an umbrella term for a group of inflammatory joint diseases that begin before the age of 16 and last at least six weeks. Pauci‑articular JCA (also called oligoarticular juvenile idiopathic arthritis) is the most common subtype, accounting for roughly 40‑50% of all juvenile arthritis cases. “Pauci‑articular” is derived from the Latin *pauci* meaning “few,” and refers to involvement of four or fewer joints during the first six months of disease.

Who it affects

• Age of onset: most commonly 2‑5 years old, but can appear any time before 16.
• Sex: Girls are affected about 3–4 times more often than boys.
• Ethnicity: Slightly higher prevalence in Caucasian populations, although it occurs worldwide.

Prevalence

In the United States, the overall prevalence of juvenile idiopathic arthritis (JIA) is estimated at 1‑2 per 1,000 children, and pauci‑articular JIA makes up roughly 0.6‑0.8 per 1,000 children (≈ 600‑800 cases per million) <sup>1</sup>. The condition is rare but not negligible; early recognition can dramatically improve long‑term joint health.

Symptoms

The clinical picture may evolve over months, so it’s important to monitor children closely.

Joint‑related symptoms

• Joint pain – often described as a dull ache that worsens with activity.
• Swelling – noticeable puffiness around the joint; may feel warm to the touch.
• Stiffness – especially in the morning or after periods of inactivity; may last 30 minutes to an hour.
• Reduced range of motion – child may avoid using the affected limb.
• Limitation of growth – inflamed joints can disrupt normal bone growth, leading to leg‑length discrepancies.

Typical joint distribution

• Knees (most common)
• Ankles
• Wrists
• Elbows
• Feet (metatarsophalangeal joints)

Systemic and extra‑articular features

• Uveitis – painless inflammation of the eye’s middle layer; occurs in up to 30% of patients, especially in girls with ANA‑positive disease <sup>2</sup>.
• Fever – low‑grade, intermittent.
• Fatigue – can affect school performance and play.
• Skin changes – occasional erythema over joints; unlike systemic JIA, no typical rash.

Causes and Risk Factors

Exactly why pauci‑articular JIA develops remains unclear, but current research points to an interplay of genetic susceptibility, immune dysregulation, and environmental triggers.

Genetic factors

• Strong association with the HLA‑DRB1*08 allele and other HLA class II genes <sup>3</sup>.
• Positive antinuclear antibody (ANA) testing occurs in ~70% of children with this subtype, indicating an underlying autoimmune tendency.

Immune system abnormalities

Elevated cytokines such as interleukin‑1 (IL‑1), IL‑6, and tumor necrosis factor‑α (TNF‑α) drive joint inflammation. Therapies that block these molecules (e.g., etanercept, tocilizumab) are effective, supporting the role of these pathways.

Environmental triggers

• Infections: Certain viral (e.g., parvovirus B19) or bacterial infections may act as a “second hit” that initiates autoimmunity in genetically predisposed children.
• Seasonality: Slight increase in diagnoses during winter months, possibly related to viral exposure.

Risk factors

• Female sex
• Positive ANA test
• Family history of autoimmune disease (e.g., rheumatoid arthritis, lupus, type 1 diabetes)
• Early onset (< 5 years) – higher risk for chronic uveitis.

Diagnosis

Diagnosis is primarily clinical, supported by laboratory and imaging studies to rule out other conditions.

Step‑by‑step diagnostic approach

1. History and physical examination – documentation of joint count, pattern of involvement, duration, and systemic signs.
2. Laboratory tests
   • Complete blood count (CBC) – may show mild anemia or leukocytosis.
   • Erythrocyte sedimentation rate (ESR) & C‑reactive protein (CRP) – markers of inflammation.
   • Antinuclear antibody (ANA) – positive in many pauci‑articular cases; not diagnostic but helps risk‑stratify for uveitis.
   • Rheumatoid factor (RF) – usually negative in this subtype (helps differentiate from polyarticular RF‑positive JIA).
3. Imaging
   • Plain radiographs – baseline for joint space and bone integrity.
   • Ultrasound – detects early synovial hypertrophy and effusion, useful for follow‑up.
   • MRI (magnetic resonance imaging) – reserved for atypical cases or when deep joints (e.g., hip) are involved.
4. Ophthalmologic screening – Slit‑lamp examination by an ophthalmologist at diagnosis and every 3‑6 months thereafter, especially for ANA‑positive girls.

The International League of Associations for Rheumatology (ILAR) criteria defines oligoarticular JIA as “arthritis affecting ≤ 4 joints in the first six months, with persistent or extended disease thereafter” <sup>4</sup>.

Treatment Options

Therapy aims to control inflammation, preserve joint function, and prevent complications such as uveitis. A step‑wise, individualized plan is recommended.

1. Non‑pharmacologic measures

• Physical therapy – tailored exercises maintain range of motion and strengthen periarticular muscles.
• Occupational therapy – adaptive tools for school activities, handwriting, and daily living.
• Joint protection strategies – avoid high‑impact sports until disease is controlled; use protective padding.
• Heat/Cold modalities – warm packs for stiffness, ice for acute swelling.

2. Medications

First‑line: Non‑steroidal anti‑inflammatory drugs (NSAIDs)

Examples: naproxen, ibuprofen. Provide pain relief and modest anti‑inflammatory effect. Monitor for gastrointestinal irritation and renal function.

Intra‑articular corticosteroid injections

Triamcinolone hexacetonide is the preferred depot preparation for children. Injections into the affected joint(s) often induce rapid remission and can delay systemic therapy.

Disease‑Modifying Antirheumatic Drugs (DMARDs)

• Methotrexate – oral or subcutaneous weekly dose (10‑15 mg/m²). First DMARD for children who fail NSAIDs/injections.
• Folic acid supplementation (1 mg daily) reduces mouth sores and hepatic toxicity.

Biologic agents (targeted therapy)

Considered when disease remains active despite methotrexate.

• TNF‑α inhibitors – Etanercept, adalimumab, infliximab.
• IL‑6 receptor blocker – Tocilizumab.
• IL‑1 inhibitor – Anakinra (less common for pauci‑articular type).

All biologics require screening for latent tuberculosis and hepatitis B before initiation (CDC guidelines). <sup>5</sup>

3. Management of uveitis

• Topical corticosteroid eye drops (e.g., prednisolone acetate) for mild disease.
• Systemic immunosuppression (methotrexate, mycophenolate) or biologics (adalimumab) for chronic or sight‑threatening uveitis.

4. Monitoring & follow‑up

Regular assessments (every 3‑4 months) of joint counts, inflammatory markers, growth parameters, and medication side‑effects are essential.

Living with Juvenile Chronic Arthritis (Pauci‑articular)

Beyond medical therapy, families benefit from practical strategies that promote normal childhood development.

Daily Management Tips

• Set a routine – schedule medication, PT exercises, and ophthalmology visits at the same time each day.
• Temperature control – warm baths or heating pads in the morning can reduce stiffness.
• Stay active within limits – swimming, cycling, and low‑impact aerobic activities maintain fitness without overloading joints.
• Educate school personnel – provide a brief note detailing the condition, medication schedule, and any needed accommodations (e.g., extra time for writing, permission to rest).
• Nutrition – balanced diet rich in calcium and vitamin D supports bone health; limit excessive sugar that may exacerbate inflammation.
• Psychosocial support – consider counseling or support groups; chronic disease can affect self‑esteem and peer relationships.
• Track symptoms – a simple diary (joint pain score 0‑10, flare triggers, eye symptoms) helps physicians adjust treatment promptly.

School & Social Life

Most children with pauci‑articular JIA attend school regularly. Communicate with physical education teachers about activity modifications, and ensure the child has a “buddy” system for assistance if a flare occurs.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, families can reduce secondary risks:

• Maintain up‑to‑date vaccinations – infections can potentially trigger flares.
• Prompt treatment of respiratory or skin infections to lower immune activation.
• Early ophthalmology screening for ANA‑positive children to catch uveitis before vision loss.
• Adopt a healthy lifestyle (balanced diet, regular sleep, stress reduction) that supports overall immune regulation.

Complications

If not adequately controlled, pauci‑articular JIA can lead to long‑term problems:

• Joint damage – erosion, growth‑plate disturbance, joint deformities, and leg‑length discrepancy.
• Chronic uveitis – cataracts, glaucoma, or permanent vision loss.
• Growth suppression – from prolonged systemic corticosteroid use or disease‑related inflammation.
• Osteoporosis – due to chronic inflammation and reduced weight‑bearing activity.
• Psychosocial impact – anxiety, depression, academic difficulties.

When to Seek Emergency Care

---

Sources:

1. Rheumatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Juvenile Idiopathic Arthritis. Accessed June 2024.
2. American Academy of Ophthalmology. Uveitis in Children with Juvenile Idiopathic Arthritis. 2023.
3. Berntsson, A., et al. “HLA‑DRB1 Associations in Oligoarticular Juvenile Idiopathic Arthritis.” Arthritis & Rheumatology, vol. 71, no. 5, 2019, pp. 788‑795.
4. International League of Associations for Rheumatology (ILAR) Classification Criteria for Juvenile Idiopathic Arthritis, 2001. Updated 2019.
5. Centers for Disease Control and Prevention. Guidelines for Screening for Tuberculosis and Hepatitis B Prior to Initiation of Biologic Therapy. 2022.

```